前往化源商城

80259-18-3 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:L1210
External ID: CHEMBL703726
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1982
Volume: 25
Issue: 3
First Page: 276
Last Page: 315
DOI: 10.1021/jm00345a015

Target ChEMBL ID: CHEMBL386
ChEMBL Target Name: L1210
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard Value
Log 1/D50=5.09
Log 1/D50=4.37
Log 1/D50=5.58
Log 1/D50=4.27
Log 1/D50=5.04
Log 1/D50<3
Log 1/D50=4.39
Log 1/D50<3
Log 1/D50<3.37
Log 1/D50=4.77
Log 1/D50=3.61
Log 1/D50=4.9
Log 1/D50=4.35
Log 1/D50<3.31
Log 1/D50=4.94
Log 1/D50=5.24
Log 1/D50=5.09
Log 1/D50=5.15
Log 1/D50=3.76
Log 1/D50=4.14
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Plasmodium falciparum
External ID: CHEMBL2448810
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL364
ChEMBL Target Name: Plasmodium falciparum
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: Medicines for Malaria Venture (MMV) Malaria Box
Standard TypeStandard RelationStandard Value
Ratio=1.022
Ratio=1.015
Ratio=1
Ratio=0.6667
Ratio=0.8734
Ratio=0.8
Ratio=0.7564
Ratio=1.105
Ratio=0.8889
Ratio=1
Ratio=0.7253
Ratio=1.104
Ratio=0.8919
Ratio=1.5
Ratio=1.066
Ratio=1.052
Ratio=1.02
Ratio=1.032
Ratio=0.6522
Ratio=0.9841
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Plasmodium yoelii
External ID: CHEMBL1789906
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Science
Year: 2011
Volume: 334
Issue: 6061
First Page: 1372
Last Page: 1377
DOI: 10.1126/science.1211936

Target ChEMBL ID: CHEMBL612889
ChEMBL Target Name: Plasmodium yoelii
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
Schizont size=39.14um62.50 pixels
0.0381IC50=38.1nM
Schizont size=69.2um110.50 pixels
0.01152IC50=11.52nM
Schizont size=24.32um38.83 pixels
0.0491IC50=49.1nM
Schizont size=13.88um22.17 pixels
10IC50>10000nM
Schizont size=246.12um393.00 pixels
0.0911IC50=91.1nM
Schizont size=61.06um97.50 pixels
0.058IC50=58nM
Schizont size=90.91um145.17 pixels
10IC50>10000nM
Schizont size=17.54um28.00 pixels
0.0045IC50=4.5nM
Schizont size=37.89um60.50 pixels
0.433IC50=433nM
Schizont size=27.24um43.50 pixels
Schizont sizeNot Determined
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Plasmodium yoelii
External ID: CHEMBL1789905
Protocol: N/A
Comment: Journal: Science
Year: 2011
Volume: 334
Issue: 6061
First Page: 1372
Last Page: 1377
DOI: 10.1126/science.1211936

Target ChEMBL ID: CHEMBL612889
ChEMBL Target Name: Plasmodium yoelii
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeActivity Comment
ActivityInactive
ActivityInactive
ActivityInactive
ActivityInactive
ActivityInactive
ActivityInactive
ActivityInactive
ActivityActive
ActivityInactive
ActivityInactive
ActivityActive
ActivityInactive
ActivityActive
ActivityActive
ActivityActive
ActivityInactive
ActivityInactive
ActivityInactive
ActivityInactive
ActivityActive
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Cryptosporidium parvum
External ID: CHEMBL3137357
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL612855
ChEMBL Target Name: Cryptosporidium parvum
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: Medicines for Malaria Venture (MMV) Malaria Box
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
Inhibition=79.74%
Inhibition=-2.54%
Inhibition=-4.075%
Inhibition=73.84%
Inhibition=-45.62%Outside typical range
Inhibition=7.066%
Inhibition=55.64%
Inhibition=-19.28%Outside typical range
Inhibition=-13.35%Outside typical range
Inhibition=-16.47%Outside typical range
Inhibition=-55.29%Outside typical range
Inhibition=-51.26%Outside typical range
Inhibition=-10.13%Outside typical range
Inhibition=27.1%
Inhibition=4.698%
Inhibition=-4.73%
Inhibition=-5.937%
Inhibition=-4.981%
Inhibition=41.18%
Inhibition=13.55%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Onchocerca lienalis
External ID: CHEMBL3137382
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL2093136
ChEMBL Target Name: Onchocerca lienalis
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: Medicines for Malaria Venture (MMV) Malaria Box
Standard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
Motility=100%Activity score: 0.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=66.6%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Onchocerca lienalis
External ID: CHEMBL3137383
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL2093136
ChEMBL Target Name: Onchocerca lienalis
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: Medicines for Malaria Venture (MMV) Malaria Box
Standard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Onchocerca lienalis
External ID: CHEMBL3137384
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL2093136
ChEMBL Target Name: Onchocerca lienalis
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: Medicines for Malaria Venture (MMV) Malaria Box
Standard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Onchocerca lienalis
External ID: CHEMBL3137385
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL2093136
ChEMBL Target Name: Onchocerca lienalis
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: Medicines for Malaria Venture (MMV) Malaria Box
Standard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
Motility=100%Activity score: 1.0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Lysine-specific histone demethylase 1A
External ID: CHEMBL5627636
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Eur J Med Chem
Year: 2023
Volume: 259
First Page: 115684
Last Page: 115684
DOI: 10.1016/j.ejmech.2023.115684

Target ChEMBL ID: CHEMBL6136
ChEMBL Target Name: Lysine-specific histone demethylase 1A
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.079IC50=79nM
0.021IC50=21nM
10IC50>10000nM
0.22IC50=220nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsp2-p
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM Peptide 2 substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2. Four uL nsP2pro enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3. The plate was incubated at room temperature (protected from light) for 15 min
4. Four microliter of peptide 2 substrate (2.5 uM final concentration) in assay buffer was added to the plate.
5. After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading..

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000040000 uMActivity at 0.0000163452 uMActivity at 0.0000320000 uMActivity at 0.0000806082 uMActivity at 0.0001439601 uMActivity at 0.0003895389 uMActivity at 0.0007288991 uMActivity at 0.00154 uMActivity at 0.00290 uMActivity at 0.00454 uMActivity at 0.00833 uMActivity at 0.021 uMActivity at 0.041 uMActivity at 0.095 uMActivity at 0.199 uMActivity at 0.321 uMActivity at 0.689 uMActivity at 1.028 uMActivity at 2.684 uMActivity at 5.101 uMActivity at 10.05 uMActivity at 24.85 uMActivity at 39.21 uMActivity at 78.39 uMActivity at 125.0 uMCompound QC
Inactive000458.411643.591625.884333.42079.110921.639545.688610.891128.395531.312738.991441.655858.4116QC'd by Sytravon
Inactive0004-12.6805-10.7548-9.5107-10.6418-15.9997-12.6805QC'd by Sytravon
Inactive0004-7.1462-9.2235-11.8601-6.118-12.2196-7.1462QC'd by Sytravon
Inactive0-4.754.95490.6661-22.0013-240 0 0 0 0-18.751-10.987-0.99352.3561.2583-18.751QC'd by Sytravon
Inactive0004-11.1249-10.2692-11.5229-11.032-13.325-11.1249QC'd by Sytravon
Inactive0-4.81.88510.5555-23.9168-5.408840 0 0 0 0-18.264-13.0121-2.8407-6.6548-7.1687-18.264QC'd by Sytravon
Inactive0-6.354.95490.9083-3.1815-14.928340 0 0 0 1-10.2909-13.1276-17.0236-1.4012-4.6174-10.2909QC'd by Sytravon
Inactive0-5.950.40.9812-20.7272-0.994240 0 0 0 0-16.0227-4.9952-8.1266-9.7286-14.3153-16.0227QC'd by Sytravon
Inactive0-6.54.95490.6409-9.2158-16.601140 0 0 0 1-12.7654-16.3342-16.1896-6.0131-13.084-12.7654QC'd by Sytravon
Inactive00041.9752.61033.4198-3.47481.76241.975QC'd by Sytravon
Inactive0004-8.2223-0.1456-4.3339-1.582-3.6253-8.2223QC'd by Sytravon
Inactive0-7.254.95490.602-10.0715240 0 0 0 0-12.60110.2325-14.2262-4.5441-8.7364-12.6011QC'd by Sytravon
Inactive0-4.754.50450.9809-24.6554-10.844240 0 0 0 0-22.2129-9.8702-10.3098-11.7375-10.6121-22.2129QC'd by Sytravon
Inactive0-4.754.95490.8409-13.5514240 0 0 0 0-11.2928-1.92764.61061.33364.0275-11.2928QC'd by Sytravon
Inactive0-5.20.50.9077-28.8252-9.445240 0 0 0 0-23.1876-10.7877-12.0613-16.7104-16.3414-23.1876QC'd by Sytravon
Inactive0004-18.3436-16.2788-21.7212-19.8613-16.6894-18.3436QC'd by Sytravon
Inactive0004-5.4025-9.518-0.16940.2848-4.8162-5.4025QC'd by Sytravon
Inactive0004-23.1229-14.0834-13.5556-16.7644-18.8145-23.1229QC'd by Sytravon
Inactive0-4.953.29750.9426-35.5663-15.226240 0 0 0 0-34.2687-12.6885-18.3414-14.0693-16.4909-34.2687QC'd by Sytravon
Inactive0-4.754.95490.7952-15.6253-4.893240 0 0 0 0-13.8544-4.3645-8.5252-3.661-3.9903-13.8544QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:flap endonuclease 1 [Homo sapiens]
External ID: fen1-ases-set-p1_selected
Protocol: Three uL of reagents (buffer in column 3 and 4 as negative control and 10 nM FEN1 in columns 1, 2, and 5-48) were dispensed into 1,536-well black solid-bottomed plate. Compounds (23 nL) were transferred via Kalypsys pin tool equipped with 1536-pin array (10 nL slotted pins, V&P Scientific, San Diego, CA). The plates were then incubated for 15 min at room temperature, and 1 uL substrate (50 nM final concentration) were added to start the reaction read twice at 0 min read and 15 min on ViewLux reader equipped with 525 nm excitation and 598 nm emission filters. Throughout the screen, reagent bottle and all liquid lines were chilled and made light-tight to minimize reagent degradation.

FEN1 Substrate. All oligodeoxynucleotides were purchased from Biosearch Technologies, Inc., (Novato, CA). Double-stranded DNA substrate containing double flap strands for fluorogenic assay was prepared from three oligodeoxynucleotides: quencher (5'-TCA CCC TCG TAC GAC TCA TCC AAA AAA GC - BHQ2), flap (5'-Tamra-GC AAA AAA TTT ATT CAT CAA CTG ACA TCT CCT AC) and template (5'-GT AGG AGA TGT CAG TTG ATG AAT TGA GTC GTA CGA GGG TGA-3') strand by annealing. The 5' end of the downstream flap strand was labeled with 6-carboxytetramethyl rhodamine (6-TAMRA) as the fluorophore donor, whereas the 3' end of the quencher flap strand was labeled with a Black Hole Quencher-2 (BHQ-2) as the matching quencher.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00368 uMActivity at 0.092 uMActivity at 0.460 uMActivity at 2.300 uMActivity at 11.50 uMActivity at 57.50 uMActivity at 115.0 uMCompound QC
Inhibitor67.455597.828842Partial curve; high efficacy-4.1713.51170.9924-94.29383.535-2.10 0 0 0 0 0 0-81.66190.0721.16642.37416.94137.6375-31.4523-81.6619QC'd by "NCGCChem"
Inhibitor30.131392.222780Complete curve; high efficacy-4.5214.95490.9994-95.1336-2.9109-1.10 0 0 0 0 0 0-95.5156-1.8617-2.9028-4.1558-3.4768-1.6903-91.5019-95.5156QC'd by "NCGCChem"
Inhibitor0.106999.664292Complete curve; high efficacy-6.9711.3310.9984-95.6524.0122-1.10 0 0 0 0 0 0-98.40741.8976-39.6603-83.04-92.5998-94.5606-94.7465-98.4074QC'd by "NCGCChem"
Inhibitor67.455561.005221Partial curve; partial efficacy-4.1712.30310.9929-68.3134-7.3082-2.20 0 0 0 0 0 0-54.7828-7.6473-6.2316-10.3712-5.2999-8.0837-32.0301-54.7828QC'd by "Asinex Ltd."
Inhibitor21.331368.590181Complete curve; high efficacy-4.6712.12110.9947-68.9499-0.3598-1.10 0 0 0 0 0 0-66.62490.50091.9731-5.0032-0.0716-15.1281-62.0653-66.6249QC'd by "Asinex Ltd."
Inhibitor11.995597.253782Complete curve; high efficacy-4.92110.9928-90.75376.5-1.10 0 0 0 0 0 0-82.24018.39297.8323-3.1525-5.664-43.0492-72.4298-82.2401QC'd by "Chem Div"
Inhibitor75.686370.331410Single point of activity-4.1214.95490.9313-57.733312.5981-30 0 0 0 0 0 0-50.11268.83221.077617.28520.868714.6925-1.2437-50.1126QC'd by "Chem Div"
Inhibitor84.921455.507310Single point of activity-4.0714.95490.9256-60.6734-5.166-30 0 0 0 0 0 0-51.3945-6.356-4.7859-14.5761-3.4329-1.8424-6.4858-51.3945QC'd by "Specs"
Inhibitor84.921475.491310Single point of activity-4.0714.95490.9733-81.3733-5.882-30 0 0 0 0 0 0-68.6444-12.3172-6.6565-4.1068-6.0028-6.6114-9.0989-68.6444QC'd by "DPISMR"
Inhibitor60.119898.949841Partial curve; high efficacy-4.2213.06540.9868-93.55675.3931-2.10 0 0 0 0 0 0-80.72485.27961.05570.9158.196711.4127-42.6839-80.7248QC'd by "ChemBridge"
Inhibitor84.921457.566821Partial curve; partial efficacy-4.0713.62720.9655-65.414-7.8472-2.20 0 0 0 0 0 0-51.0712-6.8548-7.9942-14.0675-5.9283-4.3092-19.2492-51.0712QC'd by "DPISMR"
Inhibitor84.921463.998810Single point of activity-4.0714.95490.8401-66.8108-2.812-30 0 0 0 0 0 0-55.4054-9.0952-17.84551.19473.73257.7147-9.1206-55.4054QC'd by "Specs"
Inhibitor75.686361.996741Partial curve; high efficacy-4.1213.92950.9695-70.768-8.7713-2.10 0 0 0 0 0 0-60.4303-8.4281-5.2075-15.9039-6.072-8.2792-24.7267-60.4303QC'd by "DPISMR"
Inhibitor42.561570.681640Partial curve; high efficacy-4.3711.3310.9659-70.47120.2104-2.10 0 0 0 0 0 0-61.81681.16173.97471.2132-4.9171-13.5826-35.5286-61.8168QC'd by "DPISMR"
Inhibitor75.686373.64242Partial curve; high efficacy-4.1212.84730.9867-79.9088-6.2667-2.10 0 0 0 0 0 0-62.8097-6.9506-1.8052-7.0835-6.1403-10.6266-28.7837-62.8097QC'd by "DPISMR"
Inhibitor95.283458.145210Single point of activity-4.0214.95490.8038-68.2179-10.0728-30 0 0 0 0 0 0-56.8483-11.814-27.4851-6.3024-4.4436-5.061-9.0547-56.8483QC'd by "Chem Div"
Inhibitor84.921493.016442Partial curve; high efficacy-4.0713.62720.9653-109.3571-16.3407-2.10 0 0 0 0 0 0-85.9726-8.8577-18.4679-25.0555-13.1313-15.9635-34.6209-85.9726QC'd by "Chem Div"
Inhibitor37.93379.371340Partial curve; high efficacy-4.42110.9899-85.5673-6.196-2.10 0 0 0 0 0 0-65.5813-10-1.9435-8.8634-10.2553-25.0803-54.0159-65.5813QC'd by "ChemBridge"
Inhibitor75.6863100.349942Partial curve; high efficacy-4.1213.19250.9958-103.6557-3.3058-2.10 0 0 0 0 0 0-82.3149-4.55110.7433-4.49-3.3556-5.2036-33.6183-82.3149QC'd by "Asinex Ltd."
Inhibitor37.93355.119220Partial curve; partial efficacy-4.42110.9859-64.7054-9.5862-2.20 0 0 0 0 0 0-53.9212-7.9038-8.9013-11.5207-12.3012-24.2885-39.6772-53.9212QC'd by "InterBioScreen"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: WRN-helicase-DNA-binding-f1
Protocol: Compounds were added to a 4 uL mixture of 50 nM DNA and 100 nM ThO via pintool transfer. The fluorescence signal (excitation 480 nm, emission 530 nm) was measured after 15 min incubation at room temperature using the ViewLux CCD imager. Compounds / series that exhibit a strong DNA binding profile are excluded from further consideration.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0009677143 uMActivity at 0.00290 uMActivity at 0.00871 uMActivity at 0.026 uMActivity at 0.078 uMActivity at 0.235 uMActivity at 0.705 uMActivity at 2.116 uMActivity at 6.349 uMActivity at 19.05 uMActivity at 57.14 uMCompound QC
Inactive0-4.51711.88510.8757-31.6659-6.591340 0 0 0 0 0 0 0 0 0 0-28.0549-7.5438-7.5899-3.0216-9.5719-8.1532-7.6821-5.5362-2.5761-9.6026-11.8662-28.0549QC'd by "NCGCChem"
Inactive03.92950.8108-15.818-7.463540 0 0 0 0 0 0 0 0 0 0-15.6817-7.5387-9.4438-8.5425-6.6219-7.047-8.1481-6.9907-6.9753-4.5529-10.4066-15.6817QC'd by "Chemical Block"
Inhibitor21.522771.848441Partial curve; high efficacy-4.66712.12110.9908-77.8503-6.0019-2.10 0 0 0 0 0 0 0 0 0 0-72.0836-3.4487-6.5646-5.0067-5.1508-5.8938-7.7844-4.6185-7.4684-13.9665-33.9543-72.0836QC'd by "Asinex Ltd."
Inhibitor38.273470.172110Single point of activity-4.41714.0950.9866-73.1546-2.9825-30 0 0 0 0 0 0 0 0 0 0-61.8596-1.0101-0.7241-2.294-1.0162-2.3366-3.5536-2.7991-3.292-8.3668-6.8273-61.8596QC'd by "Specs"
Inhibitor15.236963.986810Single point of activity-4.81712.40640.9512-65.2071-1.2203-30 0 0 0 0 0 0 0 0 1 0-62.67264.53043.3151-0.3081-4.4962-3.4634-2.1796-10.58431.7973-8.712872.1328-62.6726QC'd by "InterBioScreen"
Inactive04.95490.4139-3.2792-0.540 0 0 0 0 0 0 0 0 0 0-2.482-2.2709-2.90431.50633.1439-1.5292-0.1484-2.8301-3.9827-3.2067-2.7445-2.482QC'd by "ChemBridge"
Inactive04.50450.8845-19.6773-140 0 0 0 0 0 0 0 0 0 1-9.4602-1.9-2.5904-2.63041.4036-0.31952.3736-1.5919-4.3022-2.619-18.4811-9.4602QC'd by "Chem Div"
Activator0-4.36714.95490.8877133.6628-11.874850 0 0 0 0 0 0 0 0 0 0105.6373-0.873-4.2109-6.0767-3.8685-5.3121-3.8229-9.5287-12.6612-36.5571-33.0994105.6373QC'd by "DPISMR"
Inactive0-4.71711.96730.963-31.3513-4.436140 0 0 0 0 0 0 0 0 0 0-28.6261-6.365-5.1952-6.9805-2.7223-1.6134-2.8499-4.6352-4.6185-7.2466-18.0472-28.6261QC'd by "Chem Div"
Inactive01.46410.3602-1-12.939240 0 0 0 0 0 0 0 0 0 0-9.116-8.514-2.709-4.10960.99510.5099-0.67571.4313-0.5161.62170.1597-9.116QC'd by "Chem Div"
Inactive00.80.4171-2.7682-7.967840 0 0 0 0 0 0 0 0 0 1-7.3953-5.1982-8.3018-9.5565-7.0521-6.3351-3.6464-0.6402-3.7386-7.3031-2.0742-7.3953QC'd by "DPISMR"
Inactive03.51170.553-2-24.790840 0 0 0 0 0 0 0 0 0 0-11.2719-17.7423-3.1825-1.0867-6.29851.04790.42143.01622.3176-2.7334-5.3449-11.2719QC'd by "InterBioScreen"
Inactive00.80.4244-10.0029-140 0 0 0 0 0 0 0 0 0 11.1318-1.30831.3935-2.3731-0.0852-3.2798-3.5658-0.1704-0.6511-1.8742-6.66911.1318QC'd by "ChemBridge"
Inactive0-4.51714.50450.9502-28.019-140 0 0 0 0 0 0 0 0 0 0-26.68252.9025-1.0892-2.8964-3.0729-0.1339-1.1987-3.4867-0.5781-0.2008-3.9126-26.6825QC'd by "DPISMR"
Inhibitor24.148956.32120Partial curve; partial efficacy-4.61712.25260.9813-60.1737-3.8526-2.20 0 0 0 0 0 0 0 0 0 0-55.7163-2.9441-3.676-2.3564-4.2526-3.1825-2.0736-6.7753-6.8252-9.1983-21.4349-55.7163QC'd by "DPISMR"
Inactive04-2.4264-0.5959-0.7494-4.1219-1.7507-2.9179-2.0087-3.2434-2.3896-4.257-2.838-2.4264QC'd by "Specs"
Inactive01.62660.8443-25.7877-7.115840 0 0 0 0 0 0 0 0 0 0-19.8231-6.9722-8.2007-8.1577-9.3372-4.2632-7.4882-5.8173-6.966-8.3175-8.5878-19.8231QC'd by "Key Organics Ltd."
Inactive0-4.66712.84730.919-29.7419040 0 0 0 0 0 0 0 0 0 0-28.11821.5634-0.7075-0.2168-4.5532-3.54330.82731.69465.4947-0.7589-12.975-28.1182QC'd by "Key Organics Ltd."
Inactive04-0.0061-0.01842.0886-0.54061.08732.97323.12673.58745.76822.365-1.0689-0.0061QC'd by "ChemBridge"
Inactive04-9.5565-9.5104-11.3234-11.7484-6.4785-4.7219-2.8833-7.9433-2.7912-9.5821-5.8128-9.5565QC'd by "DPISMR"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:DNA polymerase iota [Homo sapiens]
External ID: pol-iota-ases-set-p1-selec
Protocol: Three microliters of reagents (buffer in column 3 and 4 as negative control while 10 nM Pol iota in columns 1, 2, and 5-48) were dispensed into a 1536-well black solid-bottom plate. Compounds (23 nL) were transferred via Kalypsys pin tool equipped with 1536-pin array. The plates were then incubated for 15 min at room temperature, and 1 uL of substrate was added to start the reaction for a final concentration of 50 nM. The substrate was made by the annealing of unlabeled oligodeoxynucleotide primer (59-TCACCCTCGTACGACTC-39) and TAMRA-labeled reporter strand (59-TTTTTTTTTTGC-6-TAMRA-39) to oligodeoxynucleotide template labeled with BHQ-2 (59-BHQ-2-GCAAAAAAAAAAGAGTCGTACGAGGGTGA-39) described in detail at the Yamanaka et.al. (PLOS, 2012) reference paper.
The assay plates were initially read after 0 min and again after 10 min of kinetic reaction using the PerkinElmer Viewlux reader equipped with 525 nm excitation and 598 nm emission filters.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00366 uMActivity at 0.091 uMActivity at 0.457 uMActivity at 2.290 uMActivity at 11.40 uMActivity at 57.10 uMActivity at 114.0 uMCompound QC
Inhibitor26.679592.944780Complete curve; high efficacy-4.57384.95490.9928-89.43523.5095-1.10 0 0 0 0 0 0-85.3041.35630.43012.75845.06147.7977-92.0115-85.304QC'd by "NCGCChem"
Inhibitor37.685891.212280Complete curve; high efficacy-4.42383.51170.9958-89.43231.7799-1.10 0 0 0 0 0 0-87.1667.23610.3997-1.1181.44430.1266-72.9053-87.166QC'd by "NCGCChem"
Inhibitor26.679583.739640Partial curve; high efficacy-4.57381.47810.993-76.73967-2.10 0 0 0 0 0 0-68.94977.7263.7285.200210.2134-12.2009-55.2489-68.9497QC'd by "NCGCChem"
Inhibitor23.778196.061381Complete curve; high efficacy-4.62384.95490.9975-92.52523.5361-1.10 0 0 0 0 0 0-90.00922.82651.292.37227.00121.6863-94.0297-90.0092QC'd by "Chemical Block"
Inhibitor67.015874.083241Partial curve; high efficacy-4.17383.1320.9811-75.7112-1.628-2.10 0 0 0 0 0 0-64.17512.1049-3.59891.4596-7.9087-1.8347-29.4499-64.1751QC'd by "CGeneTech"
Inhibitor75.19369.926721Partial curve; partial efficacy-4.12383.62720.9678-66.47793.4487-2.20 0 0 0 0 0 0-53.77125.63242.6482-4.7815.51147.2544-15.2875-53.7712QC'd by "Specs"
Inhibitor21.192389.146681Complete curve; high efficacy-4.67382.40640.9986-89.10350.043-1.10 0 0 0 0 0 0-87.35640.00252.2132-1.2391-2.795-15.6425-82.3909-87.3564QC'd by "Specs"
Inhibitor2.377894.029585Complete curve; high efficacy-5.62384.0450.9936-93.51180.5177-1.10 0 0 0 0 0 0-88.1264-1.19485.5185-1.9406-43.8184-98.0207-94.138-88.1264QC'd by "Specs"
Inhibitor42.284162.811540Partial curve; high efficacy-4.37382.04790.9771-66.6169-3.8054-2.10 0 0 0 0 0 0-61.6823-0.28341.3713-9.1692-6.0923-9.5903-43.8695-61.6823QC'd by "Chem Div"
Inhibitor59.727968.722721Partial curve; partial efficacy-4.22382.40640.9768-71.0032-2.2805-2.20 0 0 0 0 0 0-59.0933-1.76543.7117-8.421-2.332-3.7089-34.6408-59.0933QC'd by "Chem Div"
Inhibitor75.19384.51142Partial curve; high efficacy-4.12383.24750.9973-88.2822-3.7713-2.10 0 0 0 0 0 0-71.0471-3.0378-4.0747-1.515-4.9516-5.7983-28.3693-71.0471QC'd by "Chem Div"
Inhibitor18.887685.611681Complete curve; high efficacy-4.72381.82650.9945-90.9775-5.3659-1.10 0 0 0 0 0 0-82.9828-2.7169-5.0472-4.9456-9.4392-29.983-83.773-82.9828QC'd by "DPISMR"
Inhibitor15.003106.010682Complete curve; high efficacy-4.82381.210.9958-103.29452.7161-1.10 0 0 0 0 0 0-92.55783.65815.2811-2.2215-8.664-39.3323-89.3643-92.5578QC'd by "InterBioScreen"
Inhibitor37.685889.527340Partial curve; high efficacy-4.42382.30310.9983-85.82133.706-2.10 0 0 0 0 0 0-79.46412.71246.41591.4633.8993-1.9065-61.2431-79.4641QC'd by "DPISMR"
Inhibitor75.19370.007521Partial curve; partial efficacy-4.12383.62720.9889-67.54572.4618-2.20 0 0 0 0 0 0-54.9589-0.27545.42241.71295.80560.4527-16.1846-54.9589QC'd by "DPISMR"
Inhibitor75.19376.46342Partial curve; high efficacy-4.12383.24750.9952-81.2864-4.8233-2.10 0 0 0 0 0 0-65.7473-2.4987-4.1607-5.1603-4.7258-8.0653-26.9253-65.7473QC'd by "DPISMR"
Inhibitor47.443650.97620Partial curve; partial efficacy-4.32382.25260.9719-52.4178-1.4419-2.20 0 0 0 0 0 0-51.390.42393.0286-4.0535-3.242-6.1278-30.976-51.39QC'd by "DPISMR"
Inhibitor42.284197.61241Partial curve; high efficacy-4.37383.19250.9963-92.0855.527-2.10 0 0 0 0 0 0-90.27944.74689.17972.93013.32025.4147-62.7926-90.2794QC'd by "DPISMR"
Inhibitor67.015896.016141Partial curve; high efficacy-4.17383.19250.9956-91.74154.2746-2.10 0 0 0 0 0 0-76.69815.84023.3267.80993.75450.7561-31.6349-76.6981QC'd by "DPISMR"
Inhibitor59.727967.160321Partial curve; partial efficacy-4.22382.72020.9905-66.56770.5926-2.20 0 0 0 0 0 0-55.7331-2.50151.7542-1.26050.36773.3411-32.3571-55.7331QC'd by "DPISMR"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:IUPHAR-DB 靶标:alpha2C-adrenoceptor (Adrenoceptors) [Homo sapiens]
External ID: 27_Human
Protocol: The International Union of Basic and Clinical Pharmacology/British Pharmacological Society (IUPHAR/BPS) Guide to PHARMACOLOGY Database (GtoPdb) uses expert subcommittees to collate peer-reviewed information from the published literature regarding individual protein targets, and describes the pharmacology, genetics, function and anatomy of each target. Its pages provide a richly curated overview of the pharmacology of receptors, ion channels, enzymes and other target types, which can be found by following the external link to the GtoPdb website.

Comment: The data collected focuses on ligands at human receptors. Data are provided at rat or mouse orthologues where there are significant species differences, or where data are not yet available at the human target.

Information on individual experimental protocols can be found in the primary references listed for each ligand.

Affinity data are expressed as pKi [-log(Ki)], pKd [-log(Kd)], pIC50 [-log(IC50)], pEC50 [-log(EC50)], pKB [-log(KB)], pA2 or as a micromolar concentration range. In most cases the original concentration can be found in the primary reference.
pKi_minpKi_maxpKd_minpKd_maxpIC50_minpIC50_maxpKB_minpKB_maxTypeActionReference (PubMed ID)
9.99.9AntagonistAntagonist12388666
79.3AgonistFull agonist9605427,9760042,9824686
7.87.8AntagonistAntagonist17220913
7.67.9AntagonistAntagonist1353247,7908642
9.99.9AntagonistAntagonist1353247,8819505
5.85.8AgonistAgonist9605427
4.85.9AgonistPartial agonist9605427
10.110.1AntagonistAntagonist7996470
9.19.1AntagonistAntagonist12388666
8.59.5AntagonistAntagonist7908642,7996470,1353247
5.86.2AgonistFull agonist9605427
99AntagonistAntagonist7996470
5.46.2AgonistPartial agonist9605427
5.77.6AgonistPartial agonist9605427,9760042,9824686,9227000
7.77.7AntagonistAntagonist15771415
9.19.1AntagonistAntagonist7996470
7.77.76.76.7AntagonistAntagonist10636247,15771415
88AntagonistAntagonist20404009
6.86.8AntagonistAntagonist7996470
8.29.2AntagonistAntagonist8819505,7908642
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:WRN [Homo sapiens]
External ID: WRN-helicase-f1-selec
Protocol: Three microliter of reagents (buffer in columns 3 and 4 as negative controls; WRN at 20 nM final concentration in columns 1 and 2 as positive controls; columns 5-48 as test reactions) were dispensed into a 1536-well Greiner black plate via a solenoid-valve based nanoliter dispenser. Compounds (23 nL each in columns 5-48) and control (23 nL each in column 2 as dose-response) were transferred to the assay plate via a Kalypsys pintool equipped with a 1536-pin array. Plates were incubated for 15 min at room temperature, followed by a 1 uL addition of substrate (100 nM forked duplex oligonucleotide and 2 mM ATP final concentrations) to start reaction. The plates were transferred into a ViewLux CCD imager where the reaction was measured in a kinetic mode using the standard red fluorescence optics (excitation filter 525 nm, emission filter 598 nm). Maximum inhibition response was normalized to the positive control signal while no inhibition response was normalized to the buffer only wells.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0009677143 uMActivity at 0.00290 uMActivity at 0.00871 uMActivity at 0.026 uMActivity at 0.078 uMActivity at 0.235 uMActivity at 0.705 uMActivity at 2.116 uMActivity at 6.349 uMActivity at 19.05 uMActivity at 57.14 uMCompound QC
Inhibitor9.6138100.639442Partial curve; high efficacy-5.01711.3310.9987-95.8264.8134-2.10 0 0 0 0 0 0 0 0 0 0-87.27336.26756.00213.87856.45922.4484.08492.743-7.6537-31.3965-66.8043-87.2733QC'd by "NCGCChem"
Inhibitor30.4016112.566440Partial curve; high efficacy-4.51714.0950.9923-108.18364.3828-2.10 0 0 0 0 0 0 0 0 0 0-99.61669.95435.1323.50983.22960.98814.66015.3097.41780.6341-12.9037-99.6166QC'd by "Chemical Block"
Inhibitor17.0961136.58942Partial curve; high efficacy-4.767110.9973-128.56278.0263-2.10 0 0 0 0 0 0 0 0 0 0-97.3969.62125.66458.01495.52935.88438.58985.1742-7.5414-31.5015-63.8992-97.396QC'd by "Asinex Ltd."
Inhibitor7.636558.342322Partial curve; partial efficacy-5.11710.70.9881-60.3642-2.0219-2.20 0 0 0 0 0 0 0 0 0 0-49.09861.1207-2.3388-2.9235-5.3273-4.8887-7.8122-7.4062-20.3183-29.3-40.1007-49.0986QC'd by "Specs"
Inhibitor19.1821127.819541Partial curve; high efficacy-4.717110.9861-122.14715.6724-2.10 0 0 0 0 0 0 0 0 0 0-92.535710.5996.05215.542.25022.06395.81947.2626-11.856-30.4159-53.9417-92.5357QC'd by "InterBioScreen"
Inactive00.70.45173.51040 0 0 0 0 0 0 0 0 0 02.21916.50228.39543.11923.61584.59342.71572.45192.85546.16084.00372.2191QC'd by "ChemBridge"
Inhibitor13.579992.648842Partial curve; high efficacy-4.86711.1110.9952-86.67045.9784-2.10 0 0 0 0 0 0 0 0 0 0-70.204810.22664.68656.26945.46243.77095.10551.2725-5.4004-20.1428-50.8845-70.2048QC'd by "Chem Div"
Inhibitor19.1821237.759943Partial curve; high efficacy-4.717110.9951-243.2663-5.5064-2.10 0 0 0 0 0 0 0 0 0 0-186.8405-3.352-3.0571-7.1229-6.3935-6.9988-7.8057-17.3029-25.419-71.6325-115.2545-186.8405QC'd by "DPISMR"
Inhibitor12.103198.181142Partial curve; high efficacy-4.917110.9936-89.68118.5-2.10 0 0 0 0 0 0 0 0 0 0-71.728113.00310.87258.45455.78294.43025.00512.6547-5.6307-24.3828-53.1958-71.7281QC'd by "Chem Div"
Inhibitor17.0961103.427441Partial curve; high efficacy-4.76711.010.989-96.72386.7037-2.10 0 0 0 0 0 0 0 0 0 0-74.033111.89384.58879.66853.77534.1592.02581.55-2.1179-23.4346-45.841-74.0331QC'd by "Chem Div"
Inhibitor19.1821109.734341Partial curve; high efficacy-4.71711.10.9928-113.4601-3.7258-2.10 0 0 0 0 0 0 0 0 0 0-88.3645-0.3539-0.6931-3.967-7.816-7.816-4.955-5.8546-11.311-30.4232-57.3957-88.3645QC'd by "DPISMR"
Inhibitor0.5406130.827292Complete curve; high efficacy-6.26711.71370.9283-139.723-8.8958-1.10 0 0 0 0 0 0 0 0 0 0-111.31210.1522-3.9398-4.5147-15.8945-27.3419-36.9462-83.7504-129.9628-177.7646-130.8928-111.3121QC'd by "InterBioScreen"
Inactive0-4.61711.210.9214-37.9778-240 0 0 0 0 0 0 0 0 0 0-28.7315-2.33884.1416-3.0697-3.2808-2.5499-0.2436-7.0489-3.0047-7.6336-17.5897-28.7315QC'd by "ChemBridge"
Inhibitor21.522782.222841Partial curve; high efficacy-4.66712.40640.9685-79.17133.0514-2.10 0 0 0 0 0 0 0 0 0 0-77.61911.35295.63591.21812.24141.1044-0.58475.0024-2.8423-3.3133-26.5551-77.619QC'd by "DPISMR"
Inhibitor15.2369127.348342Partial curve; high efficacy-4.81711.10.9971-122.54094.8074-2.10 0 0 0 0 0 0 0 0 0 0-98.66427.22028.16714.76834.85291.77542.7224-1.0145-9.5536-27.9675-67.5854-98.6642QC'd by "DPISMR"
Inhibitor17.0961135.016842Partial curve; high efficacy-4.767110.9932-135.5669-0.55-2.10 0 0 0 0 0 0 0 0 0 0-104.60415.40210.4911-0.1995-3.2689-5.8471-4.4199-3.3917-17.8637-35.4665-71.4088-104.6041QC'd by "Specs"
Inhibitor24.148945.992620Partial curve; partial efficacy-4.61711.55790.9749-56.1694-10.1768-2.20 0 0 0 0 0 0 0 0 0 0-46.8079-8.1645-12.5998-6.814-10.4512-12.9374-10.5279-10.9883-10.5126-17.1578-27.8852-46.8079QC'd by "Key Organics Ltd."
Inactive0-4.66711.53860.9759-27.31840.540 0 0 0 0 0 0 0 0 0 0-22.76542.20360.01552.6381-0.450.4655-1.0552-0.031-0.1552-4.0503-10.9094-22.7654QC'd by "Key Organics Ltd."
Inhibitor13.5799115.242542Partial curve; high efficacy-4.86711.1110.9934-113.1862.0565-2.10 0 0 0 0 0 0 0 0 0 0-94.32178.5021-1.87233.11540.3991.151-1.0129-2.8699-8.8091-33.5942-64.8557-94.3217QC'd by "ChemBridge"
Inhibitor7.636536.564621Complete curve; partial efficacy-5.11711.71370.9819-40.684-4.1194-1.20 0 0 0 0 0 0 0 0 0 0-39.5222-0.5161-6.2085-6.1495-5.8251-5.2942-1.8729-3.613-7.9192-19.9528-34.4787-39.5222QC'd by "DPISMR"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:Bloom syndrome protein [Homo sapiens]
External ID: WRN-helicase-BLM-f1
Protocol: Three uL of reaction buffer (25 mM Tris-HCl pH 8.0, 50 mM NaCl, 2 mM MgCl2, 1 mM DTT, 0.01% Tween-20, and 1 nM BLM) was dispensed into a 1536-well Greiner black assay plate via solenoid-valve based nanoliter dispensers. Compounds (23 nl each in columns 5-48) and control (23 nl each in column 2 as dose-response) were transferred to the assay plate via a Kalypsys pin-tool equipped with a 1536-pin array. The plates were incubated for 15 min at room temperature, followed by the addition of 1 ul substrates (100 nM DNA and 2 mM ATP, final concentrations) to start the reaction. The plates were transferred into a ViewLux CCD imager where the reaction was measured in a discontinuous kinetic mode (two reads spaced 15 minutes apart, with intermediate room temperature incubation of the covered assay plate) using the standard red-fluorescence optics (excitation filter 525 nm, emission filter 598 nm). Enzyme-free and vehicle (DMSO) controls were included for signal normalization.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0009677143 uMActivity at 0.00290 uMActivity at 0.00871 uMActivity at 0.026 uMActivity at 0.078 uMActivity at 0.235 uMActivity at 0.705 uMActivity at 2.116 uMActivity at 6.349 uMActivity at 19.05 uMActivity at 57.14 uMCompound QC
Inhibitor8.5683103.689343Partial curve; high efficacy-5.06711.210.9869-103.68930-2.10 0 0 0 0 0 0 0 0 0 0-95.478110.0273-3.9208-2.541-2.2404-3.1831-3.1694-3.8115-13.306-44.2486-73.4153-95.4781QC'd by "NCGCChem"
Inhibitor30.4016106.355240Partial curve; high efficacy-4.51714.0950.9882-108.4516-2.0964-2.10 0 0 0 0 0 0 0 0 0 0-99.86344.9590.6831-3.31970.2732-3.224-4.9454-0.4918-3.4426-6.9536-17.1721-99.8634QC'd by "Chemical Block"
Inhibitor6.0659160.006445Partial curve; high efficacy-5.21710.50.9975-151.3058.7014-2.10 0 0 0 0 0 0 0 0 0 0-114.6259.68035.0792-0.6125-4.2277-7.5739-15.372-31.0427-50.4033-71.9002-94.8312-114.625QC'd by "Asinex Ltd."
Inhibitor15.236948.4421Partial curve; partial efficacy-4.817110.9925-60.157-11.717-2.20 0 0 0 0 0 0 0 0 0 0-50.1189-11.8312-12.2771-11.7568-12.3811-10.5975-12.8567-12.0987-19.7681-24.346-38.8823-50.1189QC'd by "Specs"
Inhibitor3.4111105.78885Complete curve; high efficacy-5.46711.210.9891-102.50523.2828-1.10 0 0 0 0 0 0 0 0 0 0-100.49538.93012.80222.2644-0.8916-0.0991-5.4911-1.302-38.3527-68.7376-88.1545-100.4953QC'd by "InterBioScreen"
Inactive010.58510.5478.540 0 0 0 0 0 0 0 0 0 12.94376.02895.88731.3020.32554.2598-1.6275-0.2972-0.6511.93891.85392.9437QC'd by "ChemBridge"
Inhibitor13.579990.343542Partial curve; high efficacy-4.86710.90.9794-90.3721-0.0286-2.10 0 0 0 0 0 0 0 0 0 0-71.11529.1707-0.2972-5.7034-0.5236-2.9012-2.7738-7.8545-14.0108-28.6442-52.6182-71.1152QC'd by "Chem Div"
Inhibitor19.1821174.545442Partial curve; high efficacy-4.71711.1110.997-188.2154-13.67-2.10 0 0 0 0 0 0 0 0 0 0-149.3773-10.2321-13.7985-15.3411-13.8126-13.756-16.0345-21.7804-22.5163-55.0665-99.3631-149.3773QC'd by "DPISMR"
Inactive03.06540.655310-3.377540 0 0 0 0 0 0 0 0 0 1-5.49755.602-2.2259-5.0642-7.7084-8.2313-4.3322-2.53963.674914.26656.349-5.4975QC'd by "Chem Div"
Activator3.827329.31280Complete curve; partial efficacy; poor fit-5.41712.18760.855530.33951.02671.40 0 0 0 0 0 0 0 0 0 024.605911.72831.3113-0.3241-2.0922-0.1915-3.72772.19548.501520.436137.277124.6059QC'd by "Chem Div"
Inhibitor7.636597.388883Complete curve; high efficacy-5.11711.13410.9989-106.1852-8.7964-1.10 0 0 0 0 0 0 0 0 0 0-98.3197-7.2404-8.5383-8.0874-9.5628-9.9044-9.8907-16.8989-26.3115-52.1038-79.7541-98.3197QC'd by "DPISMR"
Inhibitor0.9614111.964388Complete curve; high efficacy-6.017110.9948-108.71553.2487-1.10 0 0 0 0 0 0 0 0 0 0-104.73563.55543.10732.7637-0.1195-1.7927-21.9749-46.4296-67.7622-100.5677-102.1661-104.7356QC'd by "InterBioScreen"
Inhibitor27.095554.100820Partial curve; partial efficacy-4.56711.46410.962-61.088-6.9872-2.20 0 0 0 0 0 0 0 0 0 0-50.9067-1.7241-6.0642-7.1344-6.8074-7.5208-9.7057-8.0707-10.0624-15.1159-23.4691-50.9067QC'd by "ChemBridge"
Inhibitor17.0961123.730342Partial curve; high efficacy-4.76710.90.9772-120.03213.6982-2.10 0 0 0 0 0 0 0 0 0 0-90.933414.72957.1492-0.71341.739-3.6266-1.8282-4.8751-14.7741-30.2021-58.2342-90.9334QC'd by "DPISMR"
Inhibitor6.8061110.105844Partial curve; high efficacy-5.16710.80.9967-113.9489-3.8431-2.10 0 0 0 0 0 0 0 0 0 0-99.9552-4.5713-5.9755-4.4069-5.1389-6.3191-7.559-19.2411-36.9435-58.9483-77.562-99.9552QC'd by "DPISMR"
Inhibitor8.5683111.587143Partial curve; high efficacy-5.06710.70.9853-115.1201-3.533-2.10 0 0 0 0 0 0 0 0 0 0-95.93345.0096-1.886-5.8347-10.7117-10.2549-11.6252-22.16-33.7262-50.361-72.8304-95.9334QC'd by "Specs"
Inactive01.75290.6981-19.9259-13.78940 0 0 0 0 0 0 0 0 0 0-18.727-13.4227-14.0858-15.2645-13.1575-13.6143-14.1005-16.5758-16.2811-24.1049-18.1818-18.727QC'd by "Key Organics Ltd."
Inhibitor13.579975.997241Partial curve; high efficacy-4.86710.90.9986-79.4206-3.4234-2.10 0 0 0 0 0 0 0 0 0 0-62.4399-4.2032-1.9813-2.4483-3.9343-4.8401-6.0147-7.9536-15.3552-29.366-47.6083-62.4399QC'd by "Key Organics Ltd."
Inhibitor15.2369117.208642Partial curve; high efficacy-4.81710.80.9887-113.7183.4906-2.10 0 0 0 0 0 0 0 0 0 0-86.158.94368.04481.1787-2.90261.13450.6925-5.9084-16.1485-37.6602-58.1848-86.15QC'd by "ChemBridge"
Inhibitor5.406387.259884Complete curve; high efficacy-5.26711.28760.9972-95.5357-8.276-1.10 0 0 0 0 0 0 0 0 0 0-93.1148-9.5628-9.7951-8.6066-7.2404-8.7842-9.3852-10.0956-29.3443-56.2705-79.4945-93.1148QC'd by "DPISMR"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:DNA polymerase kappa [Homo sapiens]
External ID: pol-kappa-ases-set-p1_selec
Protocol: Three microliters of reagents (buffer in column 3 and 4 as negative control and 10 nM Pol-kappa in columns 1, 2, and 5-48) were dispensed into a 1536-well black solid-bottom plate. Compounds (23 nL) were transferred via Kalypsys pin tool equipped with 1536-pin array. The plates were then incubated for 15 min at room temperature, and 1 uL of substrate was added to start the reaction for a final concentration of 50 nM. The substrate was made by the annealing of unlabeled oligodeoxynucleotide primer (59-TCACCCTCGTACGACTC-39) and TAMRA-labeled reporter strand (59-TTTTTTTTTTGC-6-TAMRA-39) to oligodeoxynucleotide template labeled with BHQ-2 (59-BHQ-2-GCAAAAAAAAAAGAGTCGTACGAGGGTGA-39) described in detail at the Yamanaka et.al. (PLOS, 2012) reference paper. The assay plates were initially read after 0 min and again after 10 min of kinetic reaction using the PerkinElmer Viewlux reader equipped with 525 nm excitation and 598 nm emission filters.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00366 uMActivity at 0.091 uMActivity at 0.457 uMActivity at 2.290 uMActivity at 11.40 uMActivity at 57.10 uMActivity at 114.0 uMCompound QC
Inhibitor29.934962.460940Partial curve; high efficacy-4.52381.55790.9495-68.4701-6.0092-2.10 0 0 0 0 0 0-62.4751-11.0143-12.6259-1.88992.6172-19.0747-50.6864-62.4751QC'd by "NCGCChem"
Inhibitor42.284173.044440Partial curve; high efficacy-4.37381.78850.9617-78.2246-5.1802-2.10 0 0 0 0 0 0-68.618-13.139-9.20273.1839-1.4406-13.047-51.9364-68.618QC'd by "NCGCChem"
Inhibitor21.192363.301381Complete curve; high efficacy-4.67382.72020.943-75.9799-12.6785-1.10 0 0 0 0 0 0-68.9859-22.7965-17.4913-6.7317-5.2995-21.5155-78.4911-68.9859QC'd by "NCGCChem"
Inhibitor18.887675.53781Complete curve; high efficacy-4.72384.95490.9151-76.2745-0.7375-1.10 0 0 0 0 0 0-69.7166-2.8725-19.800415.1764.6444-5.2962-82.1986-69.7166QC'd by "NCGCChem"
Inhibitor16.833664.959421Complete curve; partial efficacy-4.77381.88510.9153-54.302810.6566-1.20 0 0 0 0 0 0-51.24121.71377.0E-421.891619.2545-13.5169-46.6358-51.2412QC'd by "NCGCChem"
Inhibitor0.670265.864386Complete curve; high efficacy-6.17381.82650.9723-67.6601-1.7958-1.10 0 0 0 0 0 0-65.44834.199-10.0999-22.6315-64.4816-61.5679-73.7594-65.4483QC'd by "NCGCChem"
Inhibitor67.015884.631321Partial curve; partial efficacy-4.17382.09370.9825-72.588912.0424-2.20 0 0 0 0 0 0-54.586716.261510.59713.603214.83844.0969-22.8714-54.5867QC'd by "Asinex Ltd."
Inhibitor53.232661.620941Partial curve; high efficacy-4.27382.72020.997-66.7685-5.1477-2.10 0 0 0 0 0 0-60.4307-5.4117-4.186-7.279-4.7061-4.6069-37.9599-60.4307QC'd by "Asinex Ltd."
Inhibitor67.015878.883621Partial curve; partial efficacy-4.17382.09370.917-76.22232.6614-2.20 0 0 0 0 0 0-57.40315.9833-8.0324-1.04153.8450-30.565-57.403QC'd by "ChemBridge"
Inhibitor8.436857.215382Complete curve; high efficacy-5.07382.25260.966-73.1626-15.9473-1.11 0 0 0 0 0 0-69.4773-37.7937-23.3913-8.4906-18.343-53.3873-76.0765-69.4773QC'd by "ChemBridge"
Inhibitor47.443661.201741Partial curve; high efficacy-4.32383.51170.9709-70.7447-9.543-2.10 0 0 0 0 0 0-73.6924-13.9659-9.6268-11.1324-12.0237-2.4307-47.9332-73.6924QC'd by "DPISMR"
Inhibitor18.887674.123981Complete curve; high efficacy-4.72383.1320.9688-83.819-9.6952-1.10 0 0 0 0 0 0-74.9957-4.658-15.7696-10.2628-10.4954-18.9827-90.7132-74.9957QC'd by "DPISMR"
Inhibitor53.232668.606441Partial curve; high efficacy-4.27383.06540.9964-65.64012.9663-2.10 0 0 0 0 0 0-60.33340.3312.43735.0043.4853.4846-34.1094-60.3334QC'd by "InterBioScreen"
Inhibitor33.587588.340240Partial curve; high efficacy-4.47381.47810.9941-72.229216.1111-2.10 0 0 0 0 0 0-63.570614.598814.570217.540217.4262-0.136-41.9943-63.5706QC'd by "Enamine"
Inhibitor23.778171.678780Complete curve; high efficacy-4.62382.33320.9944-74.4223-2.7435-1.10 0 0 0 0 0 0-72.43520-0.7365-5.1511-7.0135-12.9029-66.5745-72.4352QC'd by "DPISMR"
Inhibitor59.727973.945641Partial curve; high efficacy-4.22382.47290.9779-73.35930.5863-2.10 0 0 0 0 0 0-60.87828.25860.1909-3.514-1.99760-34.2469-60.8782QC'd by "ChemBridge"
Inhibitor0.9466110.337187Complete curve; high efficacy-6.02384.95490.9786-91.622518.7145-1.10 0 0 0 0 0 0-75.660213.673819.650520.7421-98.862-99.9968-91.5058-75.6602QC'd by "Chem Div"
Inhibitor84.367977.428842Partial curve; high efficacy-4.07383.57220.9583-85.3871-7.9583-2.10 0 0 0 0 0 0-65.4447-5.6268-2.1943-4.616-13.272-14.5325-24.0145-65.4447QC'd by "InterBioScreen"
Inhibitor59.727986.851441Partial curve; high efficacy-4.22382.24810.9965-79.44377.4077-2.10 0 0 0 0 0 0-62.45739.17729.38886.50754.59896.1067-34.4838-62.4573QC'd by "InterBioScreen"
Inhibitor6.701672.745283Complete curve; high efficacy-5.17382.12110.9838-76.0235-3.2783-1.10 0 0 0 0 0 0-69.6223-8.00231.7429-3.4087-11.3168-58.632-81.0403-69.6223QC'd by "Life Chemicals"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:gene 4 small orf - Marburg virus
External ID: VSVM-OFFLINE
Protocol: Two uL of HEK293 cell suspension are dispensed at 1000 cells/well into solid white 1536-well plates (Grenier) using a Multidrop Combi (Thermo Scientific). After addition of 23 nL compound by a pin tool (Kalypsys), the plate is incubated 1 h at 37 degrees C and then 3 uL of virus 1:100 dilution VSV-MARV is added. After 28 hr, 4 uL of assay reagent is added and the plates are read using a ViewLux (Perkin Elmer). Assays are performed in sub-saturating amounts of virus (MOI <0.5), therefore luciferase signals reflect the amount (titer) of virus able to infect the cells in presence of the compound.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000000311 uMActivity at 0.0000000880 uMActivity at 0.0000001756 uMActivity at 0.0000004972 uMActivity at 0.0000014063 uMActivity at 0.0000028127 uMActivity at 0.0000079555 uMActivity at 0.0000225014 uMActivity at 0.0000450029 uMActivity at 0.0001299230 uMActivity at 0.0003002708 uMActivity at 0.0008965874 uMActivity at 0.00268 uMActivity at 0.00700 uMActivity at 0.016 uMActivity at 0.032 uMActivity at 0.076 uMActivity at 0.219 uMActivity at 0.631 uMActivity at 1.728 uMActivity at 3.886 uMActivity at 8.589 uMActivity at 17.80 uMActivity at 49.20 uMActivity at 107.3 uMActivity at 231.0 uMCompound QC
Inactive04.95490.4153-14.5146140 0 0 0 14.685-8.53350.780711.3474-12.51224.685QC'd by "Microsource"
Activator12.589329.27050Single point of activity-4.94.95490.9612311.729530 0 0 0 030.9001-1.47541.01665.62436.608330.9001QC'd by "Microsource"
Activator8.912565.96990Partial curve; partial efficacy-5.050.60.947860.7629-5.2072.20 0 0 0 046.0767-2.32250.745918.756422.519446.0767QC'd by "Microsource"
Inactive04.95490.3508-5.42411240 0 0 0 02.8246.9985-6.3081-17.4367-1.02662.824QC'd by "Microsource"
Inactive04.0950.8518-20.6942-4.843241 0 0 0 0-16.9639-25.916-5.286-19.6983-24.7451-16.9639QC'd by "Microsource"
Inactive04.95490.8518-16.29641.540 0 0 0 14.12061.8961-0.6171-21.497-11.42484.1206QC'd by "Microsource"
Activator2.238783.66590Partial curve; partial efficacy; poor fit-5.650.50.880654.0974-29.56852.40 0 0 0 044.3794-19.3312-4.132918.849613.579244.3794QC'd by "Microsource"
Inhibitor12.589381.174742Partial curve; high efficacy-4.94.0950.9407-88.2352-7.0605-2.10 0 0 0 0-88.059-2.11412.5457-21.0606-24.383-88.059QC'd by "Microsource"
Inactive00.80.97540.51840 0 0 0 00.168615.59399.55235.23893.39690.1686QC'd by "Microsource"
Inactive04.95490.51614-11.192240 0 0 0 08.92332.0681-9.5798-21.4101-15.0678.9233QC'd by "Microsource"
Inhibitor10111.457810Partial curve; high efficacy; poor fit-54.0950.8557-88.020423.4373-2.30 0 0 0 0-86.9630.137116.114955.0816-24.8092-86.963QC'd by "Microsource"
Inhibitor12.5893111.860910Single point of activity-4.91.39870.9539-66.693445.1675-30 0 0 0 0-51.905634.889558.259132.6243.3045-51.9056QC'd by "Microsource"
Inactive049.450123.472150.1914-0.877627.49679.4501QC'd by "Microsource"
Inactive03.62720.9908-9.607722.540 0 0 0 0-9.256421.990720.604224.22328.6092-9.2564QC'd by "Microsource"
Activator0Single point of activity4.95490.354725.2512530 0 0 0 115.41425.71766.534243.23167.091915.4142QC'd by "Microsource"
Inactive04.95490.6074718.540 0 0 0 011.651512.589721.593821.22094.311811.6515QC'd by "Microsource"
Activator2.238752.78950Partial curve; partial efficacy-5.652.25260.961344.2358-8.55372.20 0 0 0 1-9.4264-2.4981-13.18211.959142.1127-9.4264QC'd by "Microsource"
Inactive04.95490.942281.190940 0 0 0 11.53164.67291.2372-2.34124.44781.5316QC'd by "Microsource"
Inhibitor35.481355.762210Single point of activity-4.454.95490.7876-42.791512.9707-30 0 0 0 0-30.683914.51513.87134.773829.0235-30.6839QC'd by "Microsource"
Inhibitor35.481349.231710Single point of activity-4.454.44950.7066-51.9324-2.7008-30 0 0 0 0-40.193-17.989111.8148-5.59920.7455-40.193QC'd by "Microsource"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: VSVL-OFFLINE
Protocol: For screening, 1000 cells in 2 ul/well were dispensed into white solid 1536-well plates (Greiner) using a solenoid-based dispenser. Following transfer of 23nl compound or DMSO vehicle by a pin tool, 3 ul/well of VSV-LV was added. The plates were centrifuged 1 min at 1000 RPM and then incubated 16 hr at 37 C and 5% CO2. After addition of 4 ul/well SteadyLite (PerkinElmer) detection reagent, the plates were incubated 10 min at ambient temperature and luminescence was measured on a ViewLux (Perkin Elmer) plate reader.

Keywords: NIH Roadmap, MLPCN, MLI, MLSMR, qHTS, NCGC, Lassa virus, luciferase, cell assay, infection
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000000311 uMActivity at 0.0000000880 uMActivity at 0.0000001756 uMActivity at 0.0000004972 uMActivity at 0.0000014063 uMActivity at 0.0000028127 uMActivity at 0.0000079555 uMActivity at 0.0000225014 uMActivity at 0.0000450029 uMActivity at 0.0001299230 uMActivity at 0.0003002708 uMActivity at 0.0008965874 uMActivity at 0.00268 uMActivity at 0.00700 uMActivity at 0.016 uMActivity at 0.032 uMActivity at 0.076 uMActivity at 0.219 uMActivity at 0.631 uMActivity at 1.728 uMActivity at 3.886 uMActivity at 8.587 uMActivity at 17.80 uMActivity at 49.20 uMActivity at 107.3 uMActivity at 231.0 uMCompound QC
Inhibitor25.118946.394520Partial curve; partial efficacy-4.62.25260.9287-51.2557-4.8612-2.20 0 0 0 0-41.1028-5.7868-8.9838-1.9677-26.4188-41.1028QC'd by "BIOMOL"
Inactive03.51170.943510-4.56740 0 0 0 1-5.6299-3.6518-3.5753-4.22256.795-5.6299QC'd by "Prestwick Chemical; Inc."
Inactive03.06540.937611-2.769540 0 0 0 1-2.8045-1.4193-3.1412-1.90487.584-2.8045QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.76251-16.740 0 0 0-0.288-12.255.019-2.495-0.288QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.83354.5-7.094640 0 0 03.0138-4.24556.66523.43423.0138QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.9930.5-16.289540 0 0 0 1-17.2531-11.90790.45770.74590.1472-17.2531QC'd by "Prestwick Chemical; Inc."
Inactive03.06540.989-13.9862-8.196440 0 0 0-13.7385-8.6044-8.0804-9.4725-13.7385QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.8435-11.2843440 0 0 0 0-11.90363.48785.23930.52915.9839-11.9036QC'd by "Prestwick Chemical; Inc."
Inactive00.80.72410.6-14.699940 0 0 0 1-12.1307-11.4165-6.1179-8.0206-2.8333-12.1307QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.86521-19.704140 0 0 0 0-4.2947-18.0867-15.93714.83952.1157-4.2947QC'd by "Prestwick Chemical; Inc."
Inhibitor14.125442.146510Single point of activity-4.854.95490.8997-40.14652-30 0 0 0 0-41.8192-2.3935.1804-2.52484.6867-41.8192QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.6566-10.2454040 0 0 0 0-10.2045-4.5492-0.09894.6103-5.6017-10.2045QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.52793-11.352240 0 0 01.078-15.7102-2.9932-14.95471.078QC'd by "Prestwick Chemical; Inc."
Inactive01.69240.91230.5-10.14740 0 0 00.4297-9.2892-3.9336-3.15660.4297QC'd by "Prestwick Chemical; Inc."
Inactive02.40640.78868-4.302940 0 0 0 05.7256-1.9822-4.4191-3.81758.01425.7256QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.9975.5-12.07640 0 0 1-6.5693-12.5633-7.49474.9219-6.5693QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.9232-18.4489-2.283740 0 0 0-16.2075-1.3456-4.9534-0.2364-16.2075QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.94812-17.564340 0 0 0 1-13.5121-12.97033.62471.45070.7522-13.5121QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.5725-10.21937.540 0 0 0 0-12.75555.8917.5423-18.51610.6587-12.7555QC'd by "Prestwick Chemical; Inc."
Inhibitor31.6228100.706940Partial curve; high efficacy-4.53.57220.9933-104.0783-3.3715-2.10 0 0 0 0-83.39610.3188-7.6251-4.9588-20.5702-83.3961QC'd by "BIOMOL"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Alpha-2C adrenergic receptor
External ID: CHEMBL1692251
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Eur. J. Med. Chem.
Year: 2011
Volume: 46
Issue: 3
First Page: 877
Last Page: 884
DOI: 10.1016/j.ejmech.2010.12.026

Target ChEMBL ID: CHEMBL1916
ChEMBL Target Name: Alpha-2c adrenergic receptor
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.03698Ki=36.98nM
0.008492Ki=8.492nM
0.38994Ki=389.94nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Plasmodium falciparum
External ID: CHEMBL1040691
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Proc Natl Acad Sci U S A
Year: 2008
Volume: 105
Issue: 26
First Page: 9059
Last Page: 9064
DOI: 10.1073/pnas.0802982105

Target ChEMBL ID: CHEMBL364
ChEMBL Target Name: Plasmodium falciparum
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: Novartis Malaria Screening
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
0.2485EC50=248.5nM
0.0688EC50=68.8nM
0.0744EC50=74.4nM
0.2605EC50=260.5nM
0.364EC50=364nM
0.342EC50=342nM
0.441EC50=441nM
0.652EC50=652nM
0.0977EC50=97.7nM
0.2631EC50=263.1nM
0.352EC50=352nM
0.01413EC50=14.13nM
1.099EC50=1099nM
0.2072EC50=207.2nM
0.0825EC50=82.5nM
0.0404EC50=40.4nM
0.0831EC50=83.1nM
0.7EC50=700nM
0.1714EC50=171.4nM
0.1067EC50=106.7nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL1040694
Protocol: N/A
Comment: Journal: Proc Natl Acad Sci U S A
Year: 2008
Volume: 105
Issue: 26
First Page: 9059
Last Page: 9064
DOI: 10.1073/pnas.0802982105

Data Source: Novartis Malaria Screening
Standard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
IFI=12.4%
IFI=0%
IFI=4.118%
IFI=6.952%
IFI=2.614%
IFI=1.163%
IFI=6.061%
IFI=1.84%
IFI=1.613%
IFI=0%
IFI=22.64%
IFI=1.075%
IFI=0%
IFI=14.16%
IFI=0%
IFI=0.7812%
IFI=3.937%
IFI=3.876%
IFI=7.092%
IFI=0.5495%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Plasmodium falciparum
External ID: CHEMBL1040692
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Proc Natl Acad Sci U S A
Year: 2008
Volume: 105
Issue: 26
First Page: 9059
Last Page: 9064
DOI: 10.1073/pnas.0802982105

Target ChEMBL ID: CHEMBL364
ChEMBL Target Name: Plasmodium falciparum
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: Novartis Malaria Screening
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
0.01422EC50=14.22nM
0.0687EC50=68.7nM
0.0837EC50=83.7nM
0.46EC50=460nM
0.442EC50=442nM
0.766EC50=766nM
1.655EC50=1655nM
0.1708EC50=170.8nM
0.958EC50=958nM
0.338EC50=338nM
0.3142EC50=314.2nM
0.627EC50=627nM
0.0841EC50=84.1nM
0.711EC50=711nM
0.2319EC50=231.9nM
0.547EC50=547nM
0.366EC50=366nM
0.1165EC50=116.5nM
1.25EC50>1250nM
1.601EC50=1601nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Huh-7
External ID: CHEMBL1040693
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Proc Natl Acad Sci U S A
Year: 2008
Volume: 105
Issue: 26
First Page: 9059
Last Page: 9064
DOI: 10.1073/pnas.0802982105

Target ChEMBL ID: CHEMBL614039
ChEMBL Target Name: Huh-7
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: Novartis Malaria Screening
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
19.61CC50=19610nM
6.25CC50>6250nM
12.42CC50=12420nM
20.22CC50=20220nM
100CC50>100000nM
100CC50>100000nM
8.94CC50=8940nM
1.587CC50=1587nM
100CC50>100000nM
25.8CC50=25800nM
0.835CC50=835nM
100CC50>100000nM
100CC50>100000nM
10CC50>10000nM
100CC50>100000nM
93.22CC50>93220nM
13.11CC50=13110nM
28.86CC50=28860nM
CC50Not Determined
37.19CC50=37190nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Mus sp.
External ID: CHEMBL813896
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1982
Volume: 25
Issue: 3
First Page: 276
Last Page: 315
DOI: 10.1021/jm00345a015

Target ChEMBL ID: CHEMBL613490
ChEMBL Target Name: Mus sp.
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard Value
Log 1/LD10=4.74
Log 1/LD10=4.02
Log 1/LD10=5.26
Log 1/LD10=3.78
Log 1/LD10=4.55
Log 1/LD10<3
Log 1/LD10=4.16
Log 1/LD10<3
Log 1/LD10=3.37
Log 1/LD10=4.2
Log 1/LD10=3.44
Log 1/LD10=3.71
Log 1/LD10=3.55
Log 1/LD10=3.31
Log 1/LD10=4.68
Log 1/LD10=4.77
Log 1/LD10=4.52
Log 1/LD10=4.59
Log 1/LD10=3.17
Log 1/LD10=3.75
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:MFC
External ID: CHEMBL5349125
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2023
Volume: 251
First Page: 115255
Last Page: 115255
DOI: 10.1016/j.ejmech.2023.115255

Target ChEMBL ID: CHEMBL5442174
ChEMBL Target Name: MFC
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeActivity Comment
ActivityActive
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:MFC
External ID: CHEMBL5349126
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2023
Volume: 251
First Page: 115255
Last Page: 115255
DOI: 10.1016/j.ejmech.2023.115255

Target ChEMBL ID: CHEMBL5442174
ChEMBL Target Name: MFC
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeActivity Comment
ActivityActive
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:MFC
External ID: CHEMBL5349123
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2023
Volume: 251
First Page: 115255
Last Page: 115255
DOI: 10.1016/j.ejmech.2023.115255

Target ChEMBL ID: CHEMBL5442174
ChEMBL Target Name: MFC
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeActivity Comment
ActivityDose-Dependent Effect
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:MFC
External ID: CHEMBL5349124
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2023
Volume: 251
First Page: 115255
Last Page: 115255
DOI: 10.1016/j.ejmech.2023.115255

Target ChEMBL ID: CHEMBL5442174
ChEMBL Target Name: MFC
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeActivity Comment
ActivityActive
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:MFC
External ID: CHEMBL5349121
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2023
Volume: 251
First Page: 115255
Last Page: 115255
DOI: 10.1016/j.ejmech.2023.115255

Target ChEMBL ID: CHEMBL5442174
ChEMBL Target Name: MFC
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeActivity Comment
ActivityDose-Dependent Effect
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:MFC
External ID: CHEMBL5349122
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2023
Volume: 251
First Page: 115255
Last Page: 115255
DOI: 10.1016/j.ejmech.2023.115255

Target ChEMBL ID: CHEMBL5442174
ChEMBL Target Name: MFC
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeActivity Comment
ActivityActive
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL5349119
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2023
Volume: 251
First Page: 115255
Last Page: 115255
DOI: 10.1016/j.ejmech.2023.115255
Standard TypeActivity Comment
ActivityActive
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL5349120
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2023
Volume: 251
First Page: 115255
Last Page: 115255
DOI: 10.1016/j.ejmech.2023.115255
Standard TypeActivity Comment
ActivityActive
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL5349117
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2023
Volume: 251
First Page: 115255
Last Page: 115255
DOI: 10.1016/j.ejmech.2023.115255
Standard TypeActivity Comment
ActivityDose-Dependent Effect
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL5349118
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2023
Volume: 251
First Page: 115255
Last Page: 115255
DOI: 10.1016/j.ejmech.2023.115255
Standard TypeActivity Comment
ActivityDose-Dependent Effect
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:BGC-823
External ID: CHEMBL5349115
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2023
Volume: 251
First Page: 115255
Last Page: 115255
DOI: 10.1016/j.ejmech.2023.115255

Target ChEMBL ID: CHEMBL614526
ChEMBL Target Name: BGC-823
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard UnitsActivity Comment
Inhibition%Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:BGC-823
External ID: CHEMBL5349116
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2023
Volume: 251
First Page: 115255
Last Page: 115255
DOI: 10.1016/j.ejmech.2023.115255

Target ChEMBL ID: CHEMBL614526
ChEMBL Target Name: BGC-823
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeActivity Comment
ActivityActive
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:BGC-823
External ID: CHEMBL5349113
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2023
Volume: 251
First Page: 115255
Last Page: 115255
DOI: 10.1016/j.ejmech.2023.115255

Target ChEMBL ID: CHEMBL614526
ChEMBL Target Name: BGC-823
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard UnitsActivity Comment
Inhibition%Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:BGC-823
External ID: CHEMBL5349114
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2023
Volume: 251
First Page: 115255
Last Page: 115255
DOI: 10.1016/j.ejmech.2023.115255

Target ChEMBL ID: CHEMBL614526
ChEMBL Target Name: BGC-823
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard UnitsActivity Comment
Inhibition%Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Lysine-specific histone demethylase 1A
External ID: CHEMBL5349111
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2023
Volume: 251
First Page: 115255
Last Page: 115255
DOI: 10.1016/j.ejmech.2023.115255

Target ChEMBL ID: CHEMBL6136
ChEMBL Target Name: Lysine-specific histone demethylase 1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard UnitsActivity Comment
Inhibition%Dose-Dependent Effect
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Lysine-specific histone demethylase 1A
External ID: CHEMBL5349112
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2023
Volume: 251
First Page: 115255
Last Page: 115255
DOI: 10.1016/j.ejmech.2023.115255

Target ChEMBL ID: CHEMBL6136
ChEMBL Target Name: Lysine-specific histone demethylase 1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard UnitsActivity Comment
Inhibition%Dose-Dependent Effect
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Lysine-specific histone demethylase 1A
External ID: CHEMBL5349109
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Eur J Med Chem
Year: 2023
Volume: 251
First Page: 115255
Last Page: 115255
DOI: 10.1016/j.ejmech.2023.115255

Target ChEMBL ID: CHEMBL6136
ChEMBL Target Name: Lysine-specific histone demethylase 1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
0.6IC50=600nM
8.23IC50=8230nM
1.05IC50=1050nM
IC50Not Determined
IC50Not Determined
1.16IC50=1160nM
3.62IC50=3620nM
0.073IC50=73nM
0.22IC50=220nM
0.11IC50=110nM
0.97IC50=970nM
1.66IC50=1660nM
0.71IC50=710nM
0.28IC50=280nM
0.23IC50=230nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Lysine-specific histone demethylase 1A
External ID: CHEMBL5349110
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2023
Volume: 251
First Page: 115255
Last Page: 115255
DOI: 10.1016/j.ejmech.2023.115255

Target ChEMBL ID: CHEMBL6136
ChEMBL Target Name: Lysine-specific histone demethylase 1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeActivity Comment
ActivityActive
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Lysine-specific histone demethylase 1A
External ID: CHEMBL5349108
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2023
Volume: 251
First Page: 115255
Last Page: 115255
DOI: 10.1016/j.ejmech.2023.115255

Target ChEMBL ID: CHEMBL6136
ChEMBL Target Name: Lysine-specific histone demethylase 1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=100%
Inhibition=100%
Inhibition=67.84%
Inhibition=100%
Inhibition=100%
Inhibition=99.17%
Inhibition=29.81%
Inhibition=4.01%
Inhibition=100%
Inhibition=57.92%
Inhibition=100%
Inhibition=100%
Inhibition=95.34%
Inhibition=100%
Inhibition=22.41%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:
External ID: HMS1303
Protocol: Prior to screening, lyophilized FITC-GIV peptide (a.a. 1671-1701) is dissolved in 100% DMSO to a concentration of 0.5 mM, then further diluted with water to a final concentration of 50 microM. One stock was prepared in batch for the entire screen and aliquoted. All protein stocks were stored at -80C. Thawing of aliquots on the day of the assay was performed rapidly at room temperature.

Prior to transfer of screening compounds, experimental wells of 384-well assay plates were pre-filled with 37.8 nM of FITC-GIV peptide (for 25 nM final concentration) in a 10 microL volume of assay buffer (50 mM Tris [pH 7.4], 100 mM NaCl, 10 mM MgCl2, 5 mM EDTA, 0.4% NP-40, 30 microM GDP, 1 mM DTT). Control wells were pre-filled with 37.8 nM of FITC-GIV peptide in 10 microL of assay buffer containing either 1% DMSO (vehicle negative control) or 45.3 microM AlCl3+15.1 mM NaF (AlF4- positive control). Each plate contained 16 negative control and 16 positive control wells. Plates were centrifuged at 1000xg for 2 minutes to eliminate bubbling on the surface. Following, 100 nL of experimental compound was pin-transferred into individual wells for each of two replicate assay plates (A&B). After pin-transfer, 5 microL of 3 microM His-tagged rat Galphai3 purified from E. coli (for 1 microM final concentration) was added to each well, and assay plates were shaken at low speed for 5 seconds. Final assay volume was 15 microL. Plates were centrifuged at 1000xg for 2 minutes to eliminate bubbling on the surface and shaken for 10 seconds prior to an incubation of 90 minutes at room temperature. Plates were protected from prolonged light exposure. All manipulations were performed at room temperature.

Assay plates were read with a PerkinElmer Wallac EnVision Multilabel 2103 plate reader using the fluorescent polarization measurement technology with a D505fp/D535 dual mirror and a 480 nm excitation filter. 535 nm emission filters were used for P and S channel reads at 11 mm measurement height with 30 flashes and detector gains of 319 and 563. G-factor 0.96.

Negative control: DMSO
Positive control: Aluminum tetrafluoride (AlF4-, composite of NaF and AlCl3)
Comment: Calculated result values and scoring of active compounds:

Z-score: Indicates the number of standard deviations an experimental condition is from the mean. It is calculated based on plate average (u) and standard deviation (s) of experimental well fluorescence polarization (FP) measurements for each replicate. Z-score (z) is defined as the quotient of the mean of the experimental well population subtracted from an individual well's FP (x), divided by the standard deviation within the experimental wells; z = (x-u)/s.

Normalized percent control: calculated by subtracting plate average positive control FP from experimental well FP, dividing by the difference between plate average negative and positive control FP, and multiplying by 100.

STD: the number of standard deviations from the plate average negative control FP for each replicate experimental well

Compound wells with FP values exceeding +5 standard deviations from the negative control sample average were flagged as potential aggregators or fluorescence quenchers due to their high polarization signal (HighPol) and were excluded from further consideration. Activity scores were calculated by averaging the replicate normalized percent of control values and subtracting from 100 (score based on single replicate if data for other replicate was excluded for any reason). Result values < 0 were set to 0 (no activity) and > 100 were set to 100 (100% activity). Compounds with activity score >= 15 were considered active.
mP_AFluorTotal_APchan_ASchan_AmP_BFluorTotal_BPchan_BSchan_BZ-score_AZ-score_BPercent Ctrl_APercent Ctrl_BSTD_ASTD_BNote: Polarization Artifact
122.41957988860658427448204128.11963767260572207523232-1.18225-0.63523293.2647101.541-1.80030.362745
124.61958252660565717469384129.81962517560450197535137-0.634716-0.19961197.3807104.669-0.7001171.09906
124.21966389660838267496244126.21969903460848867529262-0.734268-1.122196.632498.0451-0.90015-0.460198
1231973179861103407511118126.71971411360873537539407-1.03292-0.99397994.387398.965-1.50025-0.243634
128.11989636061370667622228130.519724618607261775793840.236366-0.0202377103.929105.9571.050181.40225
125.61986771661402087587300131.31967349360531227567249-0.3858350.1847699.2516107.429-0.2000331.74875
127.72002396861782517667466128.819866494612424676180020.136814-0.455859103.181102.8290.8501420.665934
129.21961772360456307526463132.719789155608172076257150.5101340.543507105.987110.0051.600272.35513
130.91974707560775087592059133.819696771604822176003290.9332310.82538109.167112.0292.450412.83157
127.41995714661589967639154131.119907155612592276553110.06214940.133511102.619107.0610.7001171.66213
128.61970436060754757553410127.919896451613799676204590.360806-0.686482104.864101.1731.300220.276119
126.51975466161009937552675131.21981143860959967619446-0.1618430.159136100.935107.2450.2500421.70544
125.21989803761513307595377128.51982052261116137597296-0.485388-0.53273398.5033102.277-0.4000670.535996
125.21974444761039237536601130.11961319460400397533116-0.485388-0.12273798.5033105.221-0.4000671.229
127.41996280061609707640860131.319894559612117976522010.06214940.18476102.619107.4290.7001171.74875
128.82002040261715807677242132.519888130611339976613320.4105820.492258105.239109.6371.400232.26851
128.31997122561589057653415131.820071564617330377249580.2861420.312884104.303108.3491.150191.96532
128.7197498216088940757194112919670633606278775450590.385694-0.404609105.051103.1971.350230.752559
125.719727542609617775351881291962415560487067526743-0.360947-0.40460999.4387103.197-0.1500250.752559
127.82004995261859487678056130.820021937616251676969050.1617020.0566366103.368106.5090.900151.53219
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Voltage-gated inwardly rectifying potassium channel KCNH2
External ID: CHEMBL3301459
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL240
ChEMBL Target Name: HERG
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned

Data Source: Medicines for Malaria Venture (MMV) Malaria Box
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
Inhibition=15%
Inhibition=20%
Inhibition=1%
Inhibition=0%
Inhibition=18%
Inhibition=24%
Inhibition=5%
Inhibition=-9%
Inhibition=-3%
Inhibition=1%
Inhibition=14%
Inhibition=-5%
Inhibition=9%
Inhibition=-2%
Inhibition=5%
Inhibition=-4%
Inhibition=24%
Inhibition=105%
Inhibition=-12%Outside typical range
Inhibition=-2%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Voltage-gated inwardly rectifying potassium channel KCNH2
External ID: CHEMBL3301460
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL240
ChEMBL Target Name: HERG
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned

Data Source: Medicines for Malaria Venture (MMV) Malaria Box
Standard TypeStandard RelationStandard ValueStandard UnitsActivity CommentData Validity Comment
Inhibition=19%Inactive
Inhibition=105%Highly active
Inhibition=6%Inactive
Inhibition=26%Weakly active
Inhibition=11%Inactive
Inhibition=3%Inactive
Inhibition=1%Inactive
Inhibition=69%Active
Inhibition=83%Active
Inhibition=13%Inactive
Inhibition=16%Inactive
Inhibition=7%Inactive
Inhibition=3%Inactive
Inhibition=6%Inactive
Inhibition=38%Weakly active
Inhibition=60%Active
Inhibition=95%Active
Inhibition=26%Weakly active
Inhibition=23%Inactive
Inhibition=83%Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Human immunodeficiency virus 1
External ID: CHEMBL3301474
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL378
ChEMBL Target Name: Human immunodeficiency virus 1
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: Medicines for Malaria Venture (MMV) Malaria Box
Standard TypeStandard RelationStandard ValueStandard UnitsActivity CommentData Validity Comment
Inhibition=9900%>50Outside typical range
Inhibition=500%Outside typical range
Inhibition=8100%>50Outside typical range
Inhibition=1400%Outside typical range
Inhibition=-3900%Outside typical range
Inhibition=-2400%Outside typical range
Inhibition=100%
Inhibition=5700%>50Outside typical range
Inhibition=-2900%Outside typical range
Inhibition=-1300%Outside typical range
Inhibition=6500%>50Outside typical range
Inhibition=900%Outside typical range
Inhibition=-1700%Outside typical range
Inhibition=-3100%Outside typical range
Inhibition=2800%Outside typical range
Inhibition=9600%>50Outside typical range
Inhibition=200%Outside typical range
Inhibition=-6700%Outside typical range
Inhibition=-9600%Outside typical range
Inhibition=-2600%Outside typical range
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Human immunodeficiency virus 1
External ID: CHEMBL3301473
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL378
ChEMBL Target Name: Human immunodeficiency virus 1
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: Medicines for Malaria Venture (MMV) Malaria Box
Standard TypeStandard RelationStandard ValueStandard UnitsActivity CommentData Validity Comment
Inhibition=7700%>50Outside typical range
Inhibition=-2000%Outside typical range
Inhibition=5100%>50Outside typical range
Inhibition=-6900%Outside typical range
Inhibition=-300%Outside typical range
Inhibition=-6100%Outside typical range
Inhibition=-4200%Outside typical range
Inhibition=-1000%Outside typical range
Inhibition=-8200%Outside typical range
Inhibition=-1300%Outside typical range
Inhibition=8100%>50Outside typical range
Inhibition=3000%Outside typical range
Inhibition=-6500%Outside typical range
Inhibition=-8600%Outside typical range
Inhibition=-6100%Outside typical range
Inhibition=7300%>50Outside typical range
Inhibition=-28700%Outside typical range
Inhibition=-11500%Outside typical range
Inhibition=-16700%Outside typical range
Inhibition=-14100%Outside typical range